Leriglitazone hydrochloride

Cat. No.: HY-117727A

CAS No.: 146062-46-6

Molecular Formula: $C_{19}H_{21}ClN_2O_4S$

Molecular Weight: 408.9

Target: PPAR

Pathway: Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (122.28 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.4456 mL	12.2279 mL	24.4559 mL
	5 mM	0.4891 mL	2.4456 mL	4.8912 mL
	10 mM	0.2446 mL	1.2228 mL	2.4456 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K_i of 1.2 μM. Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC_{50} of 680 nM[1].

IC_{50} & Target

PPAR-γ

REFERENCES

[1]. Mosure SA,et al. Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. J Med Chem. 2019 Feb 28;62(4):2008-2023.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA